Guangzhou Newlife New Material CO.(301323)

Search documents
新莱福(301323) - 中信证券股份有限公司关于广州新莱福新材料股份有限公司2024年度持续督导培训情况的报告
2025-01-08 07:42
中信证券股份有限公司 关于广州新莱福新材料股份有限公司 2024 年度持续督导培训情况的报告 一、培训的主要内容 (一)保荐人:中信证券股份有限公司 (二)保荐代表人:李锐、吴曦 (三)协办人:郭伟健 (四)培训时间:2024 年 12 月 30 日 (五)培训地点:广州经济技术开发区永和经济区沧海四路 4 号 (六)培训人员:李锐、吴曦 (七)培训对象:公司董事、监事、高级管理人员及上市公司控股股东和实 际控制人 (八)培训内容:本次培训结合《证券发行上市保荐业务管理办法》《深圳 证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等规则要求,重点向培训对象介绍了募集资金使用与管理、关 联交易、内幕交易、资金占用、上市公司治理、董监高信息披露职责、上市公司 董监高交易股票等相关规定,并辅以案例说明形式,加深了公司控股股东及实际 控制人、董事、监事、高级管理人员等相关人员对相关法律法规、信息披露要求 的理解。 深圳证券交易所: 中信证券股份有限公司(以下简称"中信证券"或"保荐人")根据《深圳 ...
新莱福(301323) - 关于回购公司股份进展情况的公告
2025-01-03 09:32
本公司及全体董事会成员保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 广州新莱福新材料股份有限公司(以下简称"公司")于 2024 年 2 月 6 日召开第 二届董事会第四次会议,审议通过了《关于回购公司股份方案的议案》。同意公司使用 自有资金以集中竞价交易方式回购公司部分人民币普通股 A 股股份,用于后期实施股权 激励计划或员工持股计划。本次回购股份的资金总额不低于人民币 3,000 万元(含)且 不超过人民币 6,000 万元(含),具体回购资金总额以回购期届满时实际回购股份使用 的资金总额为准。本次回购股份价格上限不超过人民币 48.86 元/股(含),回购股份 的期限为自公司董事会审议通过本次回购方案之日起 12 个月内。具体情况详见公司分 别于 2024 年 2 月 7 日、2024 年 2 月 19 日披露于巨潮资讯网(www.cninfo.com.cn)的 《关于回购公司股份方案的公告》(公告编号:2024-005)和《回购报告书》(公告编 号:2024-009)。 公司于 2024 年 6 月 21 日实施完成 2023 年年度权益 ...
新莱福:广州新莱福磁材有限公司的二期建设项目厂房主体工程已基本完工
Zheng Quan Shi Bao Wang· 2024-12-07 14:27
证券时报e公司讯,新莱福近期接受机构调研时回应"募投项目实施场地建设进度"时表示,全资子公司 广州新莱福磁材有限公司的二期建设项目厂房主体工程已基本完工,春节后,将陆续开展配套硬件设施 的安装调试工作,公司计划于明年年中完成部分场地建设并实现相关项目的投产,该新建厂房将主要用 于复合功能材料(磁胶材料、高能射线无铅防护材料等)等募投项目及研发中心重点几个新项目的中试 转产。 ...
新莱福20241203
2024-12-05 03:18
Summary of Conference Call Company Overview - The company, established in 1998, is positioned as a platform for magnetic materials applications, focusing on magnetic powder formulations and manufacturing processes [1] - In the first half of 2014, the company reported total revenue of 420 million, a year-on-year increase of 18%, with a gross profit margin of 39% and a net profit margin of 18% [1] Key Business Segments 1. Adsorption Functional Materials - Revenue for this segment in the first half of the year was 290 million, accounting for 68% of total revenue, with a gross margin close to 40% [2] - Expected stable growth of 10-20% in the future [2] - Main products include flexible magnets and printing abrasives, primarily used in advertising displays [5] 2. Electronic Ceramic Components - Revenue for this segment was 74 million, representing about 18% of total revenue, with a gross margin of 31% [2] - Focused on expanding production capacity, anticipating good growth as capacity is released [2] 3. Radiation Protection Materials - Revenue for this segment was 31 million, with a year-on-year growth of 158% [3] - The company is developing new applications for this material, which is used in medical security and nuclear industries [3] Market Position and Competitive Landscape - The company holds a leading position globally, with an estimated market share of 40% in its sector [7] - Competes with companies from the US, Japan, and domestic firms, but maintains a strong competitive edge [7] Product Development and Innovation - The company is focused on developing new products in the radiation protection materials sector, which is expected to have significant market potential [23] - The company has received FDA certification for its products in the US market, indicating strong growth prospects [17] Financial Projections - Projected revenues for 2024, 2025, and 2026 are 890 million, 1.06 billion, and 1.31 billion respectively, with year-on-year growth rates of 20% and 24% [27] - Anticipated average profit growth of around 30% in the coming years [28] Research and Development - R&D expenses increased by approximately 70% in the recent quarter, indicating a commitment to innovation [28] - The company is expected to maintain a low valuation with a PE ratio of 24 times this year and an average of 20 times in 2025, suggesting potential for upward adjustment [28] Risks and Challenges - Potential risks include trade friction, particularly with products sold in the US market [29] - Other risks involve fluctuations in raw material prices and challenges in product development [29]
新莱福:关于部分首次公开发行前已发行股份及首次公开发行战略配售股份上市流通的提示性公告
2024-12-04 11:05
证券代码:301323 证券简称:新莱福 公告编号:2024-052 广州新莱福新材料股份有限公司 关于部分首次公开发行前已发行股份及首次公开发行战略配售股份 上市流通的提示性公告 本公司及全体董事会成员保证信息披露的内容真实、准确、完整,没有虚假记载、 误导性陈述或者重大遗漏。 特别提示: 1、本次解除限售并上市流通的股份为广州新莱福新材料股份有限公司(以下简称"公 司"或"发行人"或"新莱福")部分首次公开发行前已发行股份及首次公开发行战略配售股份。 2、本次解除股份限售的股东户数为 4 户,解除限售股份的数量为 13,610,554 股,占公 司股本总额的比例为 12.9720%。 其中,解除首次公开发行前已发行股份限售的股东户数 3 户,解除限售股份的数量为 12,074,456 股,占公司股本总额的比例为 11.5079%;解除首次公开发行战略配售股份限售 的股东户数 1 户,解除限售股份的数量为 1,536,098 股,占公司股本总额的比例为 1.4640%。 3、本次解除限售股份上市流通日期为 2024 年 12 月 6 日(星期五)。 一、首次公开发行前已发行股份和上市后股份变动概况 根据中国 ...
新莱福:中信证券股份有限公司关于广州新莱福新材料股份有限公司部分首次公开发行前已发行股份及首次公开发行战略配售股份上市流通的核查意见
2024-12-04 11:05
中信证券股份有限公司 关于广州新莱福新材料股份有限公司 部分首次公开发行前已发行股份及首次公开发行战略配售 股份上市流通的核查意见 中信证券股份有限公司(以下简称"中信证券""保荐人")作为广州新 莱福新材料股份有限公司(以下简称"新莱福""公司")首次公开发行股票 并在创业板上市的保荐人,根据《证券发行上市保荐业务管理办法》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等相关规定,就公司部分首次公开发行前已发行股份及首 次公开发行战略配售股份上市流通的事项进行了核查。具体情况如下: 一、首次公开发行前已发行股份和上市后股份变动概况 根据中国证券监督管理委员会《关于同意广州新莱福新材料股份有限公司首 次公开发行股票注册的批复》(证监许可〔2023〕527 号)和深圳证券交易所《关 于广州新莱福新材料股份有限公司人民币普通股股票在创业板上市的通知》(深 证上〔2023〕468 号),公司首次向社会公众公开发行人民币普通股(A 股) 26,230,723 股,并于 2023 年 6 月 ...
新莱福:关于回购公司股份进展情况的公告
2024-12-04 11:05
广州新莱福新材料股份有限公司(以下简称"公司")于 2024 年 2 月 6 日召开第 二届董事会第四次会议,审议通过了《关于回购公司股份方案的议案》。同意公司使用 自有资金以集中竞价交易方式回购公司部分人民币普通股 A 股股份,用于后期实施股权 激励计划或员工持股计划。本次回购股份的资金总额不低于人民币 3,000 万元(含)且 不超过人民币 6,000 万元(含),具体回购资金总额以回购期届满时实际回购股份使用 的资金总额为准。本次回购股份价格上限不超过人民币 48.86 元/股(含),回购股份 的期限为自公司董事会审议通过本次回购方案之日起 12 个月内。具体情况详见公司分 别于 2024 年 2 月 7 日、2024 年 2 月 19 日披露于巨潮资讯网(www.cninfo.com.cn)的 《关于回购公司股份方案的公告》(公告编号:2024-005)和《回购报告书》(公告编 号:2024-009)。 公司于 2024 年 6 月 21 日实施完成 2023 年年度权益分派,公司 2023 年年度权益分 派实施后,公司上述回购方案中回购股份价格上限由不超过 48.86 元/股(含)调整至 不超过 4 ...
新莱福(301323) - 2024年11月21日投资者关系活动记录表
2024-11-21 11:05
High-Energy Ray Protection Materials - High-energy ray lead-free protection materials have maintained strong growth since 2023, with rapid growth in the first three quarters of 2024 [1] - Medical scatter ray protection blankets have been included in the medical insurance catalog of an overseas country, laying a solid foundation for international market expansion [1] - Nuclear emergency ray protection suits, security inspection protection materials, and food X-ray detection protection materials have been fully launched, with production and sales growing rapidly [1] - Plastic transparent radiation protection materials are accelerating production, with applications in medical ray protection glasses, face shields, mobile radiation protection screens, and more [1] Company Development and Projects - The company has successfully developed products that fill domestic gaps, promoting industry safety and generating initial performance [3] - The second phase of the Guangzhou Xinlaifu Magnetic Materials Co., Ltd. project is progressing as planned, with a total construction area exceeding 110,000 square meters [3] - The new plant is expected to be partially completed and operational by mid-next year, focusing on composite functional materials and R&D projects [3] Electronic Ceramic Materials Strategy - Electronic ceramic materials are a core focus, covering ring varistors, chip varistors, and thermistors [3] - The company aims to maintain global leadership in ring varistors and become a top-three supplier in chip varistors and thermistors [3] - Despite intense competition, the company's products maintain high capacity utilization and unique technical advantages [3] - The acquisition of Guangdong Bick in February 2023 has strengthened the company's position in large-size chip varistors, with significantly higher unit prices [3] Samarium Iron Nitrogen (SmFeN) Progress - SmFeN is being applied in magnetic data cables, watch straps, and magnetic curtains, with successful market entry [4] - Efforts are underway to increase the operating temperature of SmFeN magnets to over 120 degrees Celsius for motor applications, with ongoing development and testing [4] Financial Performance and Investments - Q3 2024 revenue increased by over 15%, with stable gross margins [4] - Q3 profit decline was influenced by increased employee compensation (2.6042 million RMB), higher R&D expenses (8.9013 million RMB), and stock-based compensation (3.4448 million RMB) [4] - The MIM project is in the early market development phase, with significant upfront investment and current losses, but strong future growth potential [4][5]
新莱福:关于回购公司股份进展情况的公告
2024-11-04 10:11
证券代码:301323 证券简称:新莱福 公告编号:2024-051 广州新莱福新材料股份有限公司 关于回购公司股份进展情况的公告 本公司及全体董事会成员保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏,并对其内容的真实性、准确性和完整性承担法律责任。 广州新莱福新材料股份有限公司(以下简称"公司")于 2024 年 2 月 6 日召开第 二届董事会第四次会议,审议通过了《关于回购公司股份方案的议案》。同意公司使用 自有资金以集中竞价交易方式回购公司部分人民币普通股 A 股股份,用于后期实施股权 激励计划或员工持股计划。本次回购股份的资金总额不低于人民币 3,000 万元(含)且 不超过人民币 6,000 万元(含),具体回购资金总额以回购期届满时实际回购股份使用 的资金总额为准。本次回购股份价格上限不超过人民币 48.86 元/股(含),回购股份 的期限为自公司董事会审议通过本次回购方案之日起 12 个月内。具体情况详见公司分 别于 2024 年 2 月 7 日、2024 年 2 月 19 日披露于巨潮资讯网(www.cninfo.com.cn)的 《关于回购公司股份方案的公告》(公告编号:202 ...
新莱福(301323) - 2024 Q3 - 季度财报
2024-10-28 08:11
Revenue and Profit - Revenue for Q3 2024 reached ¥236,089,223.99, an increase of 12.38% year-over-year, while year-to-date revenue totaled ¥652,529,212.83, up 15.75% compared to the same period last year[2] - Net profit attributable to shareholders for Q3 2024 was ¥33,041,035.45, a decrease of 24.82% year-over-year, with year-to-date net profit at ¥106,846,757.80, reflecting a slight increase of 1.98%[2] - Basic earnings per share for Q3 2024 was ¥0.32, down 23.81% from the previous year, while diluted earnings per share also stood at ¥0.32, a decrease of 23.81%[2] - The total operating revenue for the third quarter reached ¥652,529,212.83, an increase of 15.7% compared to ¥563,715,847.46 in the same period last year[12] - The company reported a net profit margin improvement, with net profit increasing to ¥120,020,195.96, compared to ¥116,784,968.63 in the previous year[12] - The net profit for Q3 2024 was CNY 107,492,530.75, a slight increase from CNY 106,517,757.18 in Q3 2023, representing a growth of approximately 0.92%[13] - Basic earnings per share decreased to CNY 1.03 from CNY 1.16 year-over-year, indicating a decline of about 11.21%[14] - Operating profit for Q3 2024 was CNY 119,681,650.59, compared to CNY 117,390,556.25 in the same period last year, reflecting an increase of approximately 1.10%[13] Assets and Liabilities - Total assets as of September 30, 2024, amounted to ¥2,215,591,185.41, representing a 1.62% increase from the end of the previous year[2] - The total assets increased slightly to ¥2,215,591,185.41 from ¥2,180,207,640.43, showing a growth of 1.6%[11] - The total liabilities decreased to ¥154,369,168.95 from ¥164,273,271.24, a reduction of 6.5%[10] - The company’s total equity attributable to shareholders increased by 2.23% to ¥2,043,528,805.30 compared to the end of the previous year[2] - The equity attributable to shareholders of the parent company rose to ¥2,043,528,805.30, up from ¥1,998,886,930.98, an increase of 2.2%[11] Cash Flow - The net cash flow from operating activities for the first nine months of 2024 was ¥87,875,017.90, reflecting a 26.42% increase year-over-year[2] - The company experienced a 102.62% decrease in net cash flow from investment activities, totaling -¥5,396,420.26, due to increased investments in financial products and construction projects[5] - Cash flow from operating activities increased to CNY 87,875,017.90, up from CNY 69,508,790.89 in Q3 2023, marking a growth of about 26.06%[15] - The net cash flow from investment activities was negative at CNY -5,396,420.26, a significant decline from CNY 205,804,448.99 in Q3 2023[16] - The company's cash and cash equivalents decreased to ¥282,690,421.66 from ¥398,213,513.90 at the beginning of the period, a decline of 29.1%[10] - The cash and cash equivalents at the end of Q3 2024 were CNY 282,690,421.66, down from CNY 1,323,736,127.45 at the end of Q3 2023, indicating a decrease of approximately 78.66%[16] - The company experienced a significant increase in cash outflows from financing activities, totaling CNY 87,054,331.87 compared to CNY 38,700,380.47 in the previous year[16] Research and Development - Research and development expenses for the first nine months of 2024 were ¥55,482,933.42, a rise of 72.58% compared to the same period last year, attributed to increased salaries and stock incentives[5] - Research and development expenses increased significantly to ¥55,482,933.42, compared to ¥32,148,446.05 in the previous year, reflecting a focus on innovation[12] Shareholder Information - As of September 30, 2024, the company repurchased a total of 1,374,690 shares, accounting for 1.3102% of the total share capital[7] - The largest shareholder, Ningbo Xinlaifu Enterprise Management Partnership, holds 34.81% of the shares, totaling 36,525,000 shares[6] - Guangzhou Yishang Investment Co., Ltd. owns 13.72% of the shares, amounting to 14,392,500 shares[6] - The company had a total of 8,357 common shareholders at the end of the reporting period[6] - The total number of restricted shares at the beginning of the period was 80,229,265, with 28,702,234 shares released during the period[8] - The company’s total outstanding shares at the end of the period were 51,527,031 after accounting for the released shares[8] - The company’s stock repurchase program is aimed at enhancing shareholder value and stabilizing the stock price[7] - The company has a significant number of shares held by foreign entities, including Jun Cai Co., Ltd. with 7.51% and Fuyi Hong Kong Co., Ltd. with 6.61%[6] - The company plans to lift restrictions on certain shares on December 5, 2024, which will affect 36,525,000 shares held by Ningbo Xinlaifu[8] - The company’s stock structure includes a mix of domestic and foreign shareholders, indicating a diverse ownership base[6] Comprehensive Income - The company reported a decrease in other comprehensive income, with a loss of -¥3,824,041.46, down 38.97% from the previous year, mainly due to foreign currency translation differences[5] - The company reported a decrease in other comprehensive income, with a net amount of CNY -1,072,371.06 compared to CNY -624,871.59 in Q3 2023[13] - The total comprehensive income for Q3 2024 was CNY 106,420,159.69, slightly up from CNY 105,892,885.59 in the same quarter last year[13]